InfuSystem (NYSE: INFU) wins CMS NOPAIN Act separate payment for pain pumps

Rhea-AI Filing Summary

InfuSystem Holdings, Inc. reported that the Centers for Medicare and Medicaid Services (CMS) has added two of the electronic infusion pumps it uses in its Pain Management services business to the list of qualifying products for separate payment under the Non-Opiods Prevent Addiction in the Nation (NOPAIN) Act. This means those specific non-opioid pain management pumps can be reimbursed separately by CMS, rather than being bundled into broader procedure payments.

The update highlights growing recognition of non-opioid pain management options within federal reimbursement programs, which may help support adoption of InfuSystem’s CMS-qualifying pumps within its Pain Management services line.

Insights

Healthcare policy and reimbursement analyst

CMS separate payment status for two infusion pumps could support InfuSystem's pain management revenue.

InfuSystem announced that CMS has added two of the electronic infusion pumps it currently uses in its Pain Management services business to the list of qualifying products for separate payment under the NOPAIN Act. Separate payment means CMS can reimburse these pumps independently from bundled procedure payments, which often improves economic incentives for hospitals and providers to use the covered devices.

The inclusion is tied specifically to non-opioid pain management under the Non-Opiods Prevent Addiction in the Nation (NOPAIN) Act, aligning InfuSystem’s equipment with a policy focus on reducing opioid reliance. Actual financial impact will depend on how widely providers adopt these CMS-qualifying pumps within InfuSystem’s Pain Management services portfolio.

Future disclosures in company communications or periodic reports may provide more detail on utilization trends for these pumps and any contribution to Pain Management segment performance following the December 10, 2025 announcement.

0001337013false00013370132025-12-102025-12-10

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (date of earliest event reported): December 10, 2025

___________________________________

InfuSystem Holdings, Inc.

(Exact name of registrant as specified in its charter)

___________________________________

Delaware (State or other jurisdiction of incorporation or organization)			001-35020 (Commission File Number)			20-3341405 (I.R.S. Employer Identification Number)
3851 West Hamlin Road Rochester Hills, Michigan 48309
(Address of principal executive offices) (Zip Code)
(248) 291-1210
(Registrant's telephone number, including area code)
			Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

___________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class			Trading Symbol(s)			Name of Each Exchange on which Registered
Common Stock, par value $.0001 per share			INFU			NYSE American LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 - Regulation FD Disclosure

On December 10, 2025, InfuSystem Holdings, Inc. (the “Company”) issued a press release announcing that the Centers for Medicare and Medicaid Services ("CMS") has added two of the electronic infusion pumps currently utilized by the Company within its Pain Management services business to the list of qualifying products for separate payment in conjunction with the Non-Opiods Prevent Addiction in the Nation ("NOPAIN") Act. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information furnished in this Item 7.01 — “Regulation FD Disclosure” of this Current Report on Form 8-K and the press release attached hereto as Exhibit 99.1 shall not be deemed “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of such section, and shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.

Item 9.01 - Financial Statements and Exhibits

(d) Exhibits

Exhibit No.						Description
99.1						Press Release of InfuSystem Holdings, Inc. dated December 10, 2025
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INFUSYSTEM HOLDINGS, INC.
By:			/s/ Barry Steele
			Barry Steele
			Chief Financial Officer

Dated: December 10, 2025

FAQ

What did CMS approve related to InfuSystem (INFU) pain management pumps?

CMS added two electronic infusion pumps that InfuSystem uses in its Pain Management services business to the list of qualifying products for separate payment under the NOPAIN Act.

What is the significance of the NOPAIN Act for InfuSystem (INFU)?

The Non-Opiods Prevent Addiction in the Nation (NOPAIN) Act supports non-opioid pain treatments. CMS now lists two InfuSystem-utilized pumps for separate payment under this program.

How could CMS separate payment status affect InfuSystem's business?

Separate payment by CMS can make qualifying infusion pumps more financially attractive for providers, which may support use of InfuSystem’s covered pumps within its Pain Management services.

Does this InfuSystem (INFU) update include new financial results?

No financial results are provided. The update focuses on CMS adding two InfuSystem-utilized infusion pumps to the NOPAIN Act separate payment list.

Is the InfuSystem CMS announcement part of a formal SEC filing?

Yes. InfuSystem reported the CMS decision in a Regulation FD disclosure and furnished the related press release as an exhibit.